Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC-guided intravesical chemotherapy versus epirubicin after TURBT for intermediate/high-risk non-muscle-invasive bladder cancer
ChiCTR2000040996Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of epirubicin in bladder cancer, transitional cell carcinoma of the bladder (TCC) and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: 3-year recurrence-free survival rate. Started Dec 2020; status: recruiting.
02
Drugs
epirubicin
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2000040996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040996.